The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) Replacement Pfizer Inc

28 May 2014 11:48

RNS Number : 2314I
Morgan Stanley Capital Services LLC
28 May 2014
 



AMENDMENT

 

 FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Morgan Stanley Capital Services LLC

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

PFIZER INC

(c) Name of the party to the offer with which exempt principal trader is connected:

 

ASTRAZENECA PLC

(d) Date dealing undertaken:

23 MAY 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

 Class of relevant security

 Purchases/sales

 Total number of securities

 Highest price per unit paid/received

 Lowest price per unit paid/received

 COMMON STOCK

 PURCHASES

 156,256

 29.6200 USD

 29.4300 USD

 COMMON STOCK

 SALES

 78,696

 29.6300 USD

 29.4400 USD

 

 

(b) Derivatives transactions (other than options)

 

 Class of relevant security

 Product description

e.g. CFD

 Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

 Number of reference securities

 Price per unit

 COMMON STOCK

 CFD

 LONG

 1,500

 29.4826 USD

 COMMON STOCK

 CFD

 LONG

 100

 29.4850 USD

 COMMON STOCK

 CFD

 LONG

 1,000

 29.4862 USD

 COMMON STOCK

 CFD

 LONG

 1,954

 29.4926 USD

 COMMON STOCK

 CFD

 LONG

 287

 29.4926 USD

 COMMON STOCK

 CFD

 LONG

 200

 29.5000 USD

 COMMON STOCK

 CFD

 LONG

 16,100

 29.5161 USD

 COMMON STOCK

 CFD

 LONG

 300

 29.5666 USD

 COMMON STOCK

 CFD

 LONG

 674

 29.5904 USD

 COMMON STOCK

 CFD

 LONG

 7,411

 29.5904 USD

 COMMON STOCK

 CFD

 LONG

 48,870

 29.5960 USD

 COMMON STOCK

 CFD

 LONG

 300

 29.6233 USD

 COMMON STOCK

 CFD

 SHORT

 112

 29.4560 USD

 COMMON STOCK

 CFD

 SHORT

 23

 29.4560 USD

 COMMON STOCK

 CFD

 SHORT

 24

 29.4566 USD

 COMMON STOCK

 CFD

 SHORT

 101

 29.4566 USD

 COMMON STOCK

 CFD

 SHORT

 100

 29.4569 USD

 COMMON STOCK

 CFD

 SHORT

 24

 29.4569 USD

 COMMON STOCK

 CFD

 SHORT

 7

 29.4590 USD

 COMMON STOCK

 CFD

 SHORT

 13

 29.4590 USD

 COMMON STOCK

 CFD

 SHORT

 3,300

 29.4728 USD

 COMMON STOCK

 CFD

 SHORT

 540

 29.4791 USD

 COMMON STOCK

 CFD

 SHORT

 3,666

 29.4791 USD

 COMMON STOCK

 CFD

 SHORT

 1,409

 29.4791 USD

 COMMON STOCK

 CFD

 SHORT

 9,561

 29.4791 USD

 COMMON STOCK

 CFD

 SHORT

 3,800

 29.4881 USD

 COMMON STOCK

 CFD

 SHORT

 45,000

 29.4900 USD

 COMMON STOCK

 CFD

 SHORT

 1

 29.4900 USD

 COMMON STOCK

 CFD

 SHORT

 6

 29.4900 USD

 COMMON STOCK

 CFD

 SHORT

 3,200

 29.4900 USD

 COMMON STOCK

 CFD

 SHORT

 2,427

 29.5000 USD

 COMMON STOCK

 CFD

 SHORT

 373

 29.5000 USD

 COMMON STOCK

 CFD

 SHORT

 58

 29.5000 USD

 COMMON STOCK

 CFD

 SHORT

 76

 29.5000 USD

 COMMON STOCK

 CFD

 SHORT

 7,100

 29.5077 USD

 COMMON STOCK

 CFD

 SHORT

 13,900

 29.5194 USD

 COMMON STOCK

 CFD

 SHORT

 3,800

 29.5194 USD

 COMMON STOCK

 CFD

 SHORT

 11,421

 29.5233 USD

 COMMON STOCK

 CFD

 SHORT

 22,500

 29.5322 USD

 COMMON STOCK

 CFD

 SHORT

 4,400

 29.5370 USD

 COMMON STOCK

 CFD

 SHORT

 100

 29.5600 USD

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

 Class of relevant security

 Product description e.g. call option

 Writing, purchasing, selling, varying etc.

 Number of securities to which option relates

 Exercise price per unit

 Type e.g. American, European etc.

 Expiry date

 Option money paid/ received per unit

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 N/A

 

(ii) Exercising

 

 Class of relevant security

 Product description e.g. call option

 Number of securities

 Exercise price per unit

 N/A

 N/A

 N/A

 N/A

 

(d) Other dealings (including subscribing for new securities)

 

 Class of relevant security

 Nature of dealing e.g. subscription, conversion

 Details

 Price per unit (if applicable)

 N/A

 N/A

 N/A

 N/A

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

Date of disclosure:

28 MAY 2014

Contact name:

Darren Wickert

Telephone number:

+44 (0)20 7425 6578

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERPGUACAUPCGUR
Date   Source Headline
2nd May 20247:00 amRNSCalquence combination improved PFS in 1L MCL
1st May 20243:00 pmRNSTotal Voting Rights
29th Apr 20247:05 amRNSTruqap recommended for EU breast cancer approval
29th Apr 20247:00 amRNSEnhertu improved PFS in HER2-low and ultralow
25th Apr 20247:00 amRNS1st Quarter Results
11th Apr 20245:30 pmRNSResult of AGM
11th Apr 20247:00 amRNSAstraZeneca increases 2024 dividend by 7%
8th Apr 20247:00 amRNSEnhertu approved in US for HER2+ solid tumours
5th Apr 20247:00 amRNSImfinzi improved OS & PFS in limited-stage SCLC
2nd Apr 20243:00 pmRNSTotal Voting Rights
2nd Apr 20247:05 amRNSVoydeya approved in US
2nd Apr 20247:00 amRNSFDA accepts Dato-DXd BLA for breast cancer
25th Mar 20247:00 amRNSUltomiris approved in the US for NMOSD
19th Mar 20247:00 amRNSAstraZeneca to acquire Fusion
14th Mar 20247:00 amRNSAstraZeneca to acquire Amolyt
12th Mar 202411:00 amRNSDirector/PDMR Shareholding
7th Mar 202411:00 amRNSNotice of AGM
6th Mar 20243:05 pmRNSDirector/PDMR Shareholding
6th Mar 20243:00 pmRNSDirector/PDMR Shareholding
4th Mar 20247:00 amRNSEMA validates Dato-DXd MAAs for NSQ NSCLC and BC
1st Mar 20243:00 pmRNSTotal Voting Rights
26th Feb 20247:00 amRNSVoydeya recommended for EU approval
22nd Feb 20241:15 pmRNSAcquisition of Gracell completed
22nd Feb 202411:00 amRNSDirector/PDMR Shareholding
22nd Feb 20247:00 amRNSAstraZeneca prices a $5bn bond offering
21st Feb 20247:00 amRNSFiling of Form 20-F with SEC
20th Feb 202411:00 amRNSAnnual Financial Report
19th Feb 20243:00 pmRNSAstraZeneca completes acquisition of Icosavax
19th Feb 20247:10 amRNSTagrisso plus chemo approved in US for lung cancer
19th Feb 20247:05 amRNSFDA accepts Dato-DXd BLA for nonsquamous NSCLC
19th Feb 20247:00 amRNSTagrisso improved PFS in Stage III lung cancer
8th Feb 20247:00 amRNSFinal Results
1st Feb 20243:00 pmRNSTotal Voting Rights
2nd Jan 20243:00 pmRNSTotal Voting Rights
27th Dec 20237:00 amRNSAstraZeneca acquires Gracell
22nd Dec 20237:00 amRNSWainua (eplontersen) granted first US FDA approval
14th Dec 20233:00 pmRNSDirector/PDMR Shareholding
12th Dec 20237:05 amRNSAstraZeneca to acquire Icosavax
1st Dec 20233:05 pmRNSBlock listing Interim Review
1st Dec 20233:00 pmRNSTotal Voting Rights
1st Dec 20237:00 amRNSDiscontinuation of two CRYSTALIZE evidence trials
23rd Nov 20233:00 pmRNSDirector/PDMR Shareholding
17th Nov 20237:00 amRNSTruqap approved in US for HR+ breast cancer
14th Nov 20237:05 amRNSUpdate on PACIFIC-2 Phase III trial for Imfinzi
9th Nov 20233:00 pmRNSDirector Declaration
9th Nov 20237:10 amRNSImfinzi combination improves PFS in liver cancer
9th Nov 20237:05 amRNSAgreement with Eccogene for clinical stage GLP-1RA
9th Nov 20237:00 amRNS9M and Q3 2023 results
1st Nov 20233:00 pmRNSTotal Voting Rights
1st Nov 20237:00 amRNSAstraZeneca cell & gene therapy deal w/ Cellectis

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.